About: Development of a TB vaccine trial site in Africa and lessons from the Ebola experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a TB vaccine trial site in Africa and lessons from the Ebola experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
Creator	Blatner, G De Steenwinkel, J Gelderbloem, S Hawkridge, T Kaguthi, G Laserson, K Mitchell, Ellen Nduba, V Okelloh, D Ouma, S Rabuogi, P Richardus, J Scott, Cherise Verver, S
source	PMC
abstract	Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died of Ebola between 2014 and 2016. Despite this manifest difference in mortality, there is now a vaccine licensed in the United States and by the European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led to the trialing of the Ebola vaccine were historic and unprecedented. The single licensed TB vaccine (BCG) has limited efficacy. There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted effort for elimination.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1186/s12889-020-09051-3
bibo:pmid	32586316
has license	cc-by
sha1sum (hex)	55cb2d0edd96f893cd0f5e11ef9b7052841eec3a
schema:url	https://doi.org/10.1186/s12889-020-09051-3
resource representing a document's title	Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
has PubMed Central identifier	PMC7316575
has PubMed identifier	32586316
schema:publication	BMC Public Health
resource representing a document's body	covid:55cb2d0edd96f893cd0f5e11ef9b7052841eec3a#body_text
is schema:about of	named entity 'vaccine' named entity 'Ebola' named entity 'additional' named entity 'INDUSTRY' named entity 'PEOPLE' named entity 'PIPELINE' named entity 'UP TO' named entity 'IS A' named entity 'GOVERNMENT' named entity 'site' named entity 'vaccine' named entity 'efficacy' named entity 'efficacy' named entity 'BCG' named entity 'licensed' named entity 'greater' named entity 'While' named entity 'United States' named entity 'pathogens' named entity 'Ebola' named entity 'European Medicines Agency' named entity 'Ebola' named entity 'vaccine' named entity 'Good Clinical Practice' named entity 'placebo' named entity 'epidemiological' named entity 'vaccines' named entity 'National Institutes of Health' named entity 'WHO' named entity 'polio' named entity '10.7' named entity 'Developing Countries' named entity 'immunogenicity' named entity 'World Health Organization' named entity 'reference ranges' named entity 'GCP' named entity 'social class' named entity 'chest radiograph' named entity 'Ebola outbreak' named entity 'West Africa' named entity 'phase IIb' named entity 'vaccination' named entity 'research teams' named entity 'phlebotomist' named entity 'North America' named entity 'prophylactic' named entity 'research teams' named entity 'Ebola vaccine' named entity 'vaccine' named entity 'dry ice' named entity 'placebo' named entity 'vaccines' named entity 'vaccine' named entity 'HDSS' named entity 'biostatistics' named entity 'Phase I trials' named entity 'human trials' named entity 'epidemiological studies' named entity 'HIV' named entity 'follow-up' named entity 'Kenya' named entity 'vaccine' named entity 'epidemic' named entity 'Ebola vaccine' named entity 'Ebola outbreak' named entity 'Ebola virus' named entity 'WHO' named entity '2014-2016'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software